Blogs Articles Organizations Biography Jack's Book Contact Information Links

Navigation: SOS Sisson > Traumatic Injury Blog

Jack Sisson's TBI Blog

A hug is duct tape for the soul.

Edge Therapeutics, Inc. announced today that it has received $100,000 in financing from the New Jersey Economic Development Authority (NJEDA) to supplement an Edison Innovation R&D Grant of $500,000 awarded to Edge in November 2009. Edge will use the funding for further development of its novel treatments to prevent secondary brain damage that often occurs after hemorrhagic stroke or traumatic brain injury (TBI).

Secondary brain injury is an indirect result of a sudden brain injury (hemorrhagic stroke or TBI) which can damage neurons that were unharmed in the primary injury. While sudden brain injury results from processes initiated directly by the stroke or TBI, secondary brain injury occurs in the hours and days following the primary injury and plays a large role in the ultimate extent of brain damage and deaths. In sudden brain injury, 80% to 90% of victims survive the initial injury, but almost half suffer secondary brain damage in the days to weeks after the event.

Current treatments to prevent secondary complications caused by sudden brain injury are limited and minimally effective, largely due to the inability to deliver adequate doses of protective drugs to the specific site of injury in the brain.

Edge Therapeutics is a privately held specialty pharmaceutical company located at the Enterprise Development Center Incubator on the campus of New Jersey Institute of Technology in Newark, NJ. The company was founded in 2009 and is supported by private investors, the New Jersey Commission on Science and Technology, and the New Jersey Economic Development Authority. Edge Therapeutics seeks to revolutionize treatment to prevent secondary brain damage after hemorrhagic stroke or TBI, by taking today's minimally effective off-patent drugs and delivering them directly to the brain via proprietary sustained-release formulations. The most advanced product, NimoGelâ„¢, consists of the generic calcium channel blocker nimodipine formulated in a biodegradable polymer carrier composed of FDA-approved materials. NimoGelâ„¢ is designed to be placed directly next to brain arteries after ruptured brain aneurysms or TBI to prevent vasospasm, a type of secondary stroke, and thereby improve patient outcomes. For more information on Edge Therapeutics, please visit
Read the entire article.

Labels: , , , , ,

TBI Film Reviews
TBI Book Reviews
Traumatic Brain Injury Law Blog
Brain Blog
Brain Blogger
SoapBlox/Chicago: Protecting Our Troops
Head Injury Survival Journal
Losing the Physical Self

Tower of Hanoi: Instructions for this popular puzzle can be viewed simply by clicking the Instructions button on that page.

May 2005   June 2005   July 2005   August 2005   September 2005   October 2005   November 2005   August 2006   September 2006   October 2006   December 2006   January 2007   February 2007   March 2007   April 2007   May 2007   June 2007   July 2007   August 2007   September 2007   October 2007   November 2007   December 2007   January 2008   February 2008   March 2008   January 2009   March 2009   April 2009   December 2009   April 2010   May 2010   June 2010   July 2010   August 2010   September 2010   October 2010   November 2010   January 2011   February 2011   March 2011   April 2011   May 2011   June 2011   July 2011   August 2011   September 2011   October 2011   November 2011   December 2011   January 2012   February 2012   March 2012   April 2012   May 2012   June 2012   October 2012   November 2012   December 2012   January 2013   February 2013   March 2013   April 2013   May 2013   June 2013   October 2013  


This page is powered by Blogger. Isn't yours?

FindingBlog - Blog Directory